Clinical Trial

Rostock International Parkinson's Disease Study (ROPAD)

Study Description

Rostock International Parkinson's Disease Study (ROPAD)

Parkinson's disease (PD) is one of the most common neurodegenerative disorders worldwide, affecting approximately 1% of individuals older than 60 years and causes progressive disability. PD is mostly considered as idiopathic disease, however more and more data suggest that it is a disease that involves interaction of genetic and environmental factors. The most common monogenic form and the one most closely resembling idiopathic PD is LRRK2 (Leucine-rich repeat kinase 2 gene) associated PD. The aims of this study are the identification of 1,500 LRRK2-positive patients, the identification of 1,500 non-LRRK2 PD patients (including a subset of ~500 patients with monogenic PD patients other than LRRK2) and the establishment of a candidate biomarker in the LRRK2-positive cohort.

Location

Locations Selected Location

Methods

No pharmaceutical medication involved No pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Genetic - Blood Test

LRRK2 hotspot mutations and the whole GBA gene will be sequenced. If LRRK2 hotspots and GBA sequencing are both negative and the subject has an early PD onset and/or a PD family history and is willing to participate in further genetic screening, 68 PD associated genes will be sequenced. In case of the negative result and if the participant has an early disease onset and/or a PD family history and is willing to participate in extended genetic screening, Whole Genome Sequencing (WGS) will be perfo ...read more on ClinicalTrials.org

Additional Information

Official Study Title

Rostock International Parkinson's Disease Study: an International, Multicenter, Epidemiological Observational Study

Clinical Trial ID

NCT03866603

ParticipAid ID

erkpBa